Differential Effects of Polyphenols on Insulin Proteolysis by the Insulin-Degrading Enzyme

• Published in: Antioxidants Vol. 10; no. 9; p. 1342
• Main Authors: Zheng, Qiuchen, Kebede, Micheal T, Lee, Bethany, Krasinski, Claire A, Islam, Saadman, Wurfl, Liliana A, Kemeh, Merc M, Ivancic, Valerie A, Jakobsche, Charles E, Spratt, Donald E, Lazo, Noel D
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25-08-2021; MDPI
• Subjects: Alzheimer's disease; Drug development; Enzymes; Epigallocatechin gallate; epigallocatechin-3-gallate; Insulin; insulin-degrading enzyme; Insulysin; Neurodegeneration; Neurodegenerative diseases; Polyphenols; Proteolysis; Resveratrol; Spectrum analysis; Substrate specificity; United States > US; insulin-degrading enzyme; epigallocatechin-3-gallate; polyphenols; resveratrol
• ISSN: 2076-3921; 2076-3921
• DOI: 10.3390/antiox10091342

The insulin-degrading enzyme (IDE) possesses a strong ability to degrade insulin and Aβ42 that has been linked to the neurodegeneration in Alzheimer's disease (AD). Given this, an attractive IDE-centric strategy for the development of therapeutics for AD is to boost IDE's activity for the clearance of Aβ42 without offsetting insulin proteostasis. Recently, we showed that resveratrol enhances IDE's activity toward Aβ42. In this work, we used a combination of chromatographic and spectroscopic techniques to investigate the effects of resveratrol on IDE's activity toward insulin. For comparison, we also studied epigallocatechin-3-gallate (EGCG). Our results show that the two polyphenols affect the IDE-dependent degradation of insulin in different ways: EGCG inhibits IDE while resveratrol has no effect. These findings suggest that polyphenols provide a path for developing therapeutic strategies that can selectively target IDE substrate specificity.